- Trial phase
- Filed/PDUFA (NDA accepted; Phase 3 completed)
- Time to market
- NDA is already under FDA review; a decision is due by May 1, 2027, with commercial launch in 2027 if approved, roughly 9 months to the binary.
- Why 6/10
- The single next hard, dated catalyst is the FDA PDUFA target action date of May 1, 2027 for the AXS-12 NDA in cataplexy/narcolepsy, a real binary ~8.5 months out on a meaningful pipeline asset, but at a company whose value is dominated by its approved AUVELITY/SUNOSI franchise, so it scores at the low end of the 6-7 band (not 8, since it is neither within 6 months nor the lead thesis-driver).
Watch for FDA communications ahead of the May 1, 2027 PDUFA, e.g., any newly scheduled advisory committee, labeling discussions, or a potential priority-review/timing change, and treat AXS-12 approval as incremental upside on top of the AUVELITY (incl. Alzheimer's agitation) and SUNOSI commercial story rather than the stock's primary thesis. Near-term share moves are more likely tied to quarterly product sales and the Alzheimer's agitation launch than to AXS-12, since its binary is ~9 months out.
Price Chart
Executive Summary
AXS-12 (reboxetine) is Axsome Therapeutics' repurposed oral treatment for cataplexy in narcolepsy. Its NDA was accepted by the FDA in July 2026 with a PDUFA target action date of May 1, 2027, and no advisory committee currently planned; it also holds Orphan Drug designation. AXS-12 is a genuine dated binary for AXSM in ~9 months, but the stock's main value drivers remain the approved products (AUVELITY and SUNOSI drove $218.4M of Q2 2026 net product revenue), making AXS-12 a meaningful but secondary catalyst, hence a neutral-to-cautiously-positive stance.
How It Works
AXS-12 is Axsome's formulation of reboxetine, an older medicine known as a selective norepinephrine reuptake inhibitor (NRI), it raises norepinephrine levels in the brain. In narcolepsy it is thought to help stabilize the abnormal REM-sleep muscle control that causes cataplexy (sudden, emotion-triggered muscle weakness) and to promote wakefulness. Reboxetine was previously marketed as an antidepressant in Europe (Edronax), so Axsome is repurposing a drug with a long human safety history rather than inventing a new chemical.
Trial Status
Phase 3 study (NCT05059223, ~90 patients) in narcolepsy/cataplexy completed March 2024 and the smaller Phase 2 CONCERT trial (NCT03881852, 21 patients) completed November 2019. NDA for cataplexy in narcolepsy was submitted May 2026, accepted for filing July 15, 2026, with a PDUFA target date of May 1, 2027; FDA does not currently plan an advisory committee meeting. AXS-12 holds FDA Orphan Drug designation for narcolepsy. Data were also presented at SLEEP 2026 (June 2026).
The Two-Sided Case
Upcoming Catalysts
- PDUFA target action date May 1, 2027 for AXS-12 NDA in cataplexy/narcolepsy (primary binary).
- Any FDA advisory-committee announcement or CRL/warning in the review window before May 2027.
- Quarterly earnings: AUVELITY/SUNOSI sales growth and Alzheimer's agitation launch trajectory (Q3 2026 report expected ~Nov 2026).
- Potential commercial-launch prep/positioning updates for AXS-12 if FDA momentum builds.
Source Filing
The SecBot filing or press-release report that triggered this drug report:
Axsome Therapeutics, Inc. Press Release AXSM ·Originating report